Anti-cancer living medicine
The living-medicine developed by the SynRx team is an anti-cancer drug targeting individual problematic genes causing cancer development with live microbes.
Our therapeutic genetic tool kit suppressing specific cancer-inducing target genes is delivered by an attenuated Salmonella preferring to live in a low oxygen environment.
Because a low oxygen environment, known as hypoxia, is one of the common features of solid cancers, facultative anaerobic bacteria are willing to colonize the cancer tissue so that the anti-cancer drug would be delivered to the targeted cancer site in a specific manner.
To clear the current medical unmet needs of cancer treatment such as mutations of target proteins, limited applications, or low efficacy etc., the scientists of SynRx will introduce the specific genetic sequences screened from individual patients to our therapeutic platform.
Our idea would be an advanced technique in the customized anti-cancer drug to dramatically increase the therapeutic outcomes.